Supplemental Material and Supplemental Figure 2. Paclitaxel is a clinically relevant
broad-spectrum anticancer agent, which was utilized in the present study for site-specific anti-angiogenesis therapy. Paclitaxel has a low solubility in water (<0.1 µg/ml) and from the synthetic stand point, chemistries involving esterification of the 2'-hydroxyl group are feasible providing a site for functionalization. (Supplemental Figure 2) The 2'-hydroxy group is the most reactive of the hydroxy groups in paclitaxel. For the synthesis of paclitaxel prodrug, several reagents were attempted for conjugating the PAzPC (1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine) through the 2"-hydroxyl group that included dicyclohexyl carbodiimide (DCC)/dimethylaminopyridine (DMAP) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/ dimethylaminopyridine (EDCI/DMAP). Between these reagents, DCC/DMAP were found to be the most efficient coupling agents and produced the desired compound in 87% yield. The compound was isolated and purified by flash chromatography utilizing a Biotage Flash+ system and the structure was confirmed by Procedure: 0.2 mL PFOB NPs containing 0.2 mole% Dxtl-PD was spiked into 1ml whole blood in 4 ml PBS and incubated at 37 ºC for 2-3 hours. Next, sample was centrifuge at 1000 rpm for 10 min. An aliquot from RBC fraction located above the dense PFOB NPs was washed 3X 4 ml PBS. 100 microliter of the washed RBC were mixed with 2-propanol (0.2 ml) and deionized water (0.2 ml), then centrifuge at 11000 
